Planned Solutions Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 31.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,063 shares of the biopharmaceutical company’s stock after buying an additional 1,435 shares during the quarter. Planned Solutions Inc.’s holdings in Pfizer were worth $318,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of PFE. Norges Bank bought a new stake in Pfizer during the fourth quarter valued at about $3,351,891,000. Capital International Investors boosted its holdings in Pfizer by 3,059.6% during the first quarter. Capital International Investors now owns 38,530,003 shares of the biopharmaceutical company’s stock valued at $1,994,698,000 after acquiring an additional 37,310,556 shares during the period. Vanguard Group Inc. boosted its holdings in Pfizer by 3.0% during the first quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock valued at $24,801,210,000 after acquiring an additional 13,790,348 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in Pfizer by 577.8% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock valued at $715,270,000 after acquiring an additional 10,440,786 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Pfizer by 28.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock valued at $2,246,359,000 after acquiring an additional 9,537,621 shares during the period. 67.90% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a report on Tuesday, June 28th. Barclays set a $50.00 target price on shares of Pfizer in a research note on Thursday, September 1st. UBS Group set a $59.00 target price on shares of Pfizer in a research note on Thursday, September 1st. Morgan Stanley reduced their target price on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a research note on Friday, July 8th. Finally, Berenberg Bank set a $44.00 price target on shares of Pfizer in a research note on Wednesday, September 14th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $57.00.
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The business had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. Pfizer’s revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.07 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio is currently 31.31%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.